Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Scotiabank Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $50
Scotiabank Remains a Buy on Twist Bioscience (TWST)
Twist Bioscience Price Target Raised to $35.00/Share From $28.00 by JP Morgan
Baird Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $46
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $46
Twist Bioscience Analyst Ratings
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $55
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), RegenXBio (RGNX)
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $65
Buy Rating Justified by Strong Demand and Strategic Expansion of Twist Bioscience's Express Genes
Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating
Goldman Sachs Maintains Buy on Twist Bioscience, Raises Price Target to $55
Twist Bioscience Analyst Ratings
Twist Bioscience Analyst Ratings
Twist Bioscience Analyst Ratings
Twist Bioscience Analyst Ratings
Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target
Scotiabank: Maintaining the Twist Bioscience (TWST.US) rating, adjusted from outperforming the market to outperforming the market rating, and the target price was adjusted from $43.00 to $48.00.